New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 16, 2014
11:57 EDTGILD, YHOOStocks with call strike movement; GILD YHOO
Gilead (GILD) January 105 call option implied volatility increased 4% to 32, Yahoo (YHOO) January 38 call option implied volatility decreased 4% to 35 according to IVolatility.
News For YHOO;GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 21, 2015
19:09 EDTYHOOYahoo CEO sees Q3 pressure on revenue ex-TAC and adjusted EBITDA
Speaking on the company's Q2 earnings conference call, Yahoo (YHOO) CEO Marissa Mayer said she is "pleased" with momentum in display business, adding that the company will continue to focus on sustaining GAAP revenue growth while striving to grow adjusted EBITDA. She noted search clicks were up 13% for the quarter, and mobile user base was up 14%. Mayer cautioned that the Gemini search platform will see pricing pressure and reduced revenue per search in the near-term as Yahoo optimizes the service. She said she expects "some" pressure in Q3 including pressure on revenue ex-TAC and adjusted EBITDA, and remarked separately that Yahoo has been investing "modestly" over the past two years in algorithmic and paid search technologies. Finally, Mayer declined to speculate on any future agreements with Google (GOOG). CFO Ken Goldman said the company's "highest priority" is to execute the Alibaba (BABA) spinoff this year. Goldman also noted that Yahoo's board of directors and management team have met with advisors to review alternatives with regards to Yahoo Japan, but had no specific conclusion to share.
19:00 EDTYHOOOn The Fly: After Hours Movers
Subscribe for More Information
16:16 EDTYHOOYahoo sees Q3 revenue ex-TAC $1B-$1.04B, consensus $1.07B
Subscribe for More Information
16:13 EDTYHOOYahoo down 2.8% to $38.61 after Q2 earnings miss expectations
Subscribe for More Information
16:11 EDTYHOOYahoo says workforce lowered to under 11,000 full-time employees
Subscribe for More Information
16:09 EDTYHOOYahoo CEO says 'extremely pleased' with Q2 achievements
Subscribe for More Information
16:08 EDTYHOOYahoo reports Q2 Ads Sold up 9%
Subscribe for More Information
16:07 EDTYHOOYahoo reports Q2 Paid Clicks up 13%
Gross search revenue was $920M for Q2, an increase of 15% compared to the second quarter of 2014. The number of Paid Clicks increased approximately 13% compared to the second quarter of 2014. Price-per-Click increased approximately 4% compared to the second quarter of 2014.
16:06 EDTYHOOYahoo reports Q2 EPS 16c, consensus 18c
Reports Q2 revenue $1.04B, consensus $1.03B.
15:02 EDTYHOONotable companies reporting after market close
Subscribe for More Information
14:25 EDTYHOOYahoo July weekly 39.50 straddle priced for 4.7% movement into Q2
14:12 EDTGILDGilead reports study of E/C/F/TAF met primary endpoint
Gilead Sciences announced detailed 48-week data from an open-label Phase 3 study evaluating its investigational once-daily single tablet regimen of elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide 10 mg, or E/C/F/TAF, among 1,436 virologically suppressed adult patients switching from tenofovir disoproxil fumarate-containing regimens. The study met its primary endpoint by demonstrating non-inferiority of E/C/F/TAF to the TDF-based regimens at Week 48. The study also demonstrated statistical superiority among patients with HIV-1 RNA levels less than 50 copies/mL at Week 48 and statistically significant improvements in bone and renal laboratory parameters. These data were presented in an oral session at the 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention in Vancouver, Canada. Among the 1,436 patients who were randomized in the study, virologic success rates at Week 48 were higher in patients taking E/C/F/TAF, 97% versus 93% for all TDF-based regimens; difference in percentages: 4.1%, 95% CI: 1.6% to 6.7%. The rates of virologic failure were similar between the two arms, with E/C/F/TAF, 1.0% and TDF-based regimen, 1.3%. General safety was similar between the two arms through 48 weeks of treatment, with similar percentages of patients in each group having any adverse events. Adverse events leading to treatment discontinuation were more common among patients treated with a TDF-based regimen.
12:59 EDTYHOOEarnings Watch: Tax questions linger into Yahoo Q2 report
Subscribe for More Information
09:56 EDTYHOOSalesforce rallies amid renewed speculation of Microsoft deal
Subscribe for More Information
06:38 EDTYHOOYahoo volatility increases into Q2 and outlook
Subscribe for More Information
06:07 EDTYHOOONUG: Yahoo hires VP of global network from Symantec
Subscribe for More Information
05:50 EDTYHOOYahoo could drop below $38 on negative tax announcement, says Piper Jaffray
Subscribe for More Information
July 20, 2015
12:20 EDTYHOOYahoo July weekly volatility increases into Q2 and outlook
Subscribe for More Information
07:33 EDTGILDInternational AIDS Society to hold a conference
Subscribe for More Information
06:59 EDTYHOOYahoo says taxes could 'materially reduce' Aabaco cash for distributions
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use